GT Biopharma (GTBP) Receivables - Other (2023 - 2026)
GT Biopharma (GTBP) posted quarterly Receivables - Other of $1.0 million for Q1 2026, down 47.37% year-over-year from $1.9 million in Q1 2025, and down 9.09% quarter-over-quarter from $1.1 million in Q4 2025.
GT Biopharma (GTBP) Receivables - Other (2023 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Receivables - Other for 4 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Other fell 47.37% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $1.0 million (down 47.37% YoY), while the FY2025 annual figure was $1.1 million, down 52.89% from the prior year.
- Receivables - Other retreated to $1.0 million in Q1 2026 per GTBP's latest filing, from $1.1 million in the prior quarter.
- Across five years, Receivables - Other topped out at $4.6 million in Q4 2023 and bottomed at $431000.0 in Q2 2025.
- Historically, Receivables - Other has averaged $1.7 million across 4 years, with a median of $1.4 million in 2024.
- Annual changes were most pronounced in 2024 — Receivables - Other plunged 60.73% — and 2025, when it slumped 38.89%.
- GT Biopharma's Receivables - Other stood at $4.6 million in 2023, then slumped by 60.73% to $1.8 million in 2024, then slumped by 38.89% to $1.1 million in 2025, then dropped by 9.09% to $1.0 million in 2026.
- Business Quant data shows GTBP's Receivables - Other at $1.0 million in Q1 2026, $1.1 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.00 Mn |
| Mar 31, 2026 | 1.00 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Jun 30, 2025 | 431,000.00 |
| Jun 30, 2025 | 431,000.00 |
| Mar 31, 2025 | 1.90 Mn |
| Mar 31, 2025 | 1.90 Mn |
| Dec 31, 2024 | 1.80 Mn |
| Dec 31, 2024 | 1.80 Mn |
| Jun 30, 2024 | 862,000.00 |
| Jun 30, 2024 | 862,000.00 |
| Dec 31, 2023 | 4.58 Mn |
| Dec 31, 2023 | 4.58 Mn |